These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 27580495)

  • 1. Comparison of Subjective Experiences and Effectiveness of First-Generation Long-Acting Injectable Antipsychotics and Risperidone Long-Acting Injectables in Patients With Schizophrenia.
    Chen WY; Lin SK
    J Clin Psychopharmacol; 2016 Oct; 36(5):492-5. PubMed ID: 27580495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study.
    Nielsen J; Jensen SO; Friis RB; Valentin JB; Correll CU
    Schizophr Bull; 2015 May; 41(3):627-36. PubMed ID: 25180312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge.
    Marcus SC; Zummo J; Pettit AR; Stoddard J; Doshi JA
    J Manag Care Spec Pharm; 2015 Sep; 21(9):754-68. PubMed ID: 26308223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Impact of drug-reimbursement policies on prescribing: A case-study of a newly marketed long-acting injectable antipsychotic among relapsed schizophrenia patients".
    Jackson JW; Fulchino L; Rogers J; Mogun H; Polinski J; Henderson DC; Schneeweiss S; Fischer MA
    Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):95-104. PubMed ID: 29168261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
    Li H; Rui Q; Ning X; Xu H; Gu N
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1002-8. PubMed ID: 21315787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Long acting injectable antipsychotics in the treatment of schizophrenia: a review of literature].
    Graffino M; Montemagni C; Mingrone C; Rocca P
    Riv Psichiatr; 2014; 49(3):115-23. PubMed ID: 25000887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study.
    Buckley PF; Schooler NR; Goff DC; Hsiao J; Kopelowicz A; Lauriello J; Manschreck T; Mendelowitz AJ; Miller del D; Severe JB; Wilson DR; Ames D; Bustillo J; Mintz J; Kane JM;
    Schizophr Bull; 2015 Mar; 41(2):449-59. PubMed ID: 24870446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of initiating long-acting injectable antipsychotics on hospitalization in patients with bipolar I disorder.
    Yan T; Greene M; Chang E; Touya M; Broder MS
    J Comp Eff Res; 2018 Nov; 7(11):1083-1093. PubMed ID: 30129771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal.
    Einarson TR; Maia-Lopes S; Goswami P; Bereza BG; Van Impe K
    J Med Econ; 2016 Sep; 19(9):913-21. PubMed ID: 27124697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent Oral Antipsychotic Drug Use Among Schizophrenia Patients Initiated on Long-Acting Injectable Antipsychotics Post-Hospital Discharge.
    Doshi JA; Pettit AR; Stoddard JJ; Zummo J; Marcus SC
    J Clin Psychopharmacol; 2015 Aug; 35(4):442-6. PubMed ID: 26075492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment discontinuation of long-acting injectables or oral atypical antipsychotics among Medicaid recipients with schizophrenia.
    Song X; El Khoury AC; Brouillette M; Smith D; Joshi K
    J Med Econ; 2019 Nov; 22(11):1105-1112. PubMed ID: 31062998
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of oral versus long-acting antipsychotics on social functioning: A psychiatrists' survey in India.
    Gundugurti PR; Nagpal R; Sheth A; Narang P; Gawande S; Singh V
    Asian J Psychiatr; 2017 Dec; 30():88-93. PubMed ID: 28843143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of long-acting risperidone in New Zealand: a report of resource utilization and costs in a 12-month mirror-image analysis.
    Carswell C; Wheeler A; Vanderpyl J; Robinson E
    Clin Drug Investig; 2010; 30(11):777-87. PubMed ID: 20712387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies.
    Haddad PM; Taylor M; Niaz OS
    Br J Psychiatry Suppl; 2009 Nov; 52():S20-8. PubMed ID: 19880913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data.
    Frey S; Linder R; Juckel G; Stargardt T
    Eur J Health Econ; 2014 Mar; 15(2):133-42. PubMed ID: 23420082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuation of schizophrenia treatment with three long-acting injectable antipsychotics in South Korea: A nationwide population-based study.
    Joo SW; Shon SH; Choi G; Koh M; Cho SW; Lee J
    Eur Neuropsychopharmacol; 2019 Sep; 29(9):1051-1060. PubMed ID: 31362852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do Long-Acting Injectable Antipsychotics Prevent or Delay Hospital Readmission?
    Maestri TJ; Mican LM; Rozea H; Barner JC
    Psychopharmacol Bull; 2018 Mar; 48(3):8-15. PubMed ID: 29713100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of risperidone in different application forms - Comparing long-acting injectable and oral formulations.
    Schoretsanitis G; de Leon J; Haen E; Stegmann B; Hiemke C; Gründer G; Paulzen M
    Eur Neuropsychopharmacol; 2018 Jan; 28(1):130-137. PubMed ID: 29153926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland.
    Einarson TR; Pudas H; Goswami P; van Impe K; Bereza BG
    J Med Econ; 2016; 19(2):111-20. PubMed ID: 26414966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia.
    Ikai S; Remington G; Suzuki T; Takeuchi H; Tsuboi T; Den R; Hirano J; Tsunoda K; Nishimoto M; Watanabe K; Mimura M; Mamo D; Uchida H
    J Clin Psychiatry; 2012 Aug; 73(8):1147-52. PubMed ID: 22967779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.